Cannara Biotech Inc.
LOVFF
$1.34
-$0.02-1.47%
OTC PK
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 28.40% | 25.18% | 30.37% | 41.53% | 49.30% |
| Total Other Revenue | 42.72% | 121.15% | -87.92% | -92.40% | -138.78% |
| Total Revenue | 28.60% | 25.23% | 30.42% | 41.61% | 49.01% |
| Cost of Revenue | 14.54% | 25.13% | 54.14% | 71.39% | 79.22% |
| Gross Profit | 51.99% | 25.36% | 2.51% | 8.47% | 16.39% |
| SG&A Expenses | 17.24% | 20.39% | 43.09% | 43.96% | 41.27% |
| Depreciation & Amortization | 25.03% | 24.52% | 15.01% | 41.58% | -16.07% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.50% | 23.06% | 49.31% | 61.18% | 63.13% |
| Operating Income | 141.98% | 37.06% | -41.44% | -36.01% | -12.11% |
| Income Before Tax | 214.98% | 111.84% | -41.96% | -37.47% | 6.93% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 182.88% | 109.88% | -28.60% | -9.91% | 6.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 182.88% | 109.88% | -28.60% | -9.91% | 6.93% |
| EBIT | 141.98% | 37.06% | -41.44% | -36.01% | -12.11% |
| EBITDA | 85.46% | 28.26% | -26.17% | -17.91% | -1.14% |
| EPS Basic | 188.97% | 115.23% | -27.19% | -7.66% | 3.40% |
| Normalized Basic EPS | 468.71% | 86.20% | -67.49% | -70.97% | -41.90% |
| EPS Diluted | 223.33% | 136.64% | -28.12% | -15.43% | -3.49% |
| Normalized Diluted EPS | 463.70% | 84.41% | -68.47% | -72.06% | -41.83% |
| Average Basic Shares Outstanding | -0.24% | -0.81% | -0.50% | 0.25% | 2.39% |
| Average Diluted Shares Outstanding | 0.76% | 0.49% | 0.34% | 1.07% | 2.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |